Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised £2.2M in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, a number of returning angels and new investors and the US-based R42 Group. This brings the firm’s total amount of grant and equity funding to over £10M.